Jpmorgan Chase & CO Protalix Bio Therapeutics, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PLX
# of Institutions
66Shares Held
9.25MCall Options Held
40.6KPut Options Held
10.1K-
Black Rock Inc. New York, NY3.31MShares$3.84 Million0.0% of portfolio
-
State Street Corp Boston, MA827KShares$958,8330.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny825KShares$956,6510.0% of portfolio
-
Geode Capital Management, LLC Boston, MA754KShares$874,7670.0% of portfolio
-
Gsa Capital Partners LLP London, X0494KShares$572,5420.05% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $57.7M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...